Edginton AN - Search Results

1

Pediatric Dose Selection for Therapeutic Proteins.

Malik PRV, Temrikar ZH, Chelle P, Edginton AN, Meibohm B. Malik PRV, et al. Among authors: edginton an. J Clin Pharmacol. 2021 Jun;61 Suppl 1:S193-S206. doi: 10.1002/jcph.1829. J Clin Pharmacol. 2021. PMID: 34185910 Review.

2

A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.

Maharaj AR, Barrett JS, Edginton AN. Maharaj AR, et al. Among authors: edginton an. AAPS J. 2013 Apr;15(2):455-64. doi: 10.1208/s12248-013-9451-0. Epub 2013 Jan 24. AAPS J. 2013. PMID: 23344790 Free PMC article.

3

The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.

Edginton AN, Shah B, Sevestre M, Momper JD. Edginton AN, et al. Clin Pharmacokinet. 2013 Aug;52(8):693-703. doi: 10.1007/s40262-013-0065-6. Clin Pharmacokinet. 2013. PMID: 23588537

4

Investigation of an alternative generic model for predicting pharmacokinetic changes during physiological stress.

Peng HT, Edginton AN, Cheung B. Peng HT, et al. Among authors: edginton an. J Clin Pharmacol. 2013 Oct;53(10):1048-57. doi: 10.1002/jcph.131. Epub 2013 Jul 12. J Clin Pharmacol. 2013. PMID: 23852614

5

A PBPK workflow for first-in-human dose selection of a subcutaneously administered pegylated peptide.

Offman E, Edginton AN. Offman E, et al. Among authors: edginton an. J Pharmacokinet Pharmacodyn. 2015 Apr;42(2):135-50. doi: 10.1007/s10928-015-9406-4. Epub 2015 Feb 4. J Pharmacokinet Pharmacodyn. 2015. PMID: 25650156

6

Predicting neonatal pharmacokinetics from prior data using population pharmacokinetic modeling.

Wang J, Edginton AN, Avant D, Burckart GJ. Wang J, et al. Among authors: edginton an. J Clin Pharmacol. 2015 Oct;55(10):1175-83. doi: 10.1002/jcph.524. Epub 2015 Jun 9. J Clin Pharmacol. 2015. PMID: 25907280

7

Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability.

Malik PRV, Hamadeh A, Phipps C, Edginton AN. Malik PRV, et al. Among authors: edginton an. J Pharmacokinet Pharmacodyn. 2017 Jun;44(3):277-290. doi: 10.1007/s10928-017-9515-3. Epub 2017 Mar 4. J Pharmacokinet Pharmacodyn. 2017. PMID: 28260166

8

Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.

Hornik CP, Wu H, Edginton AN, Watt K, Cohen-Wolkowiez M, Gonzalez D. Hornik CP, et al. Among authors: edginton an. Clin Pharmacokinet. 2017 Nov;56(11):1343-1353. doi: 10.1007/s40262-017-0525-5. Clin Pharmacokinet. 2017. PMID: 28290120 Free PMC article.

9

Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer.

Malik P, Phipps C, Edginton A, Blay J. Malik P, et al. Pharm Res. 2017 Dec;34(12):2579-2595. doi: 10.1007/s11095-017-2259-3. Epub 2017 Sep 18. Pharm Res. 2017. PMID: 28924691 Review.

10

Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis.

McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. McEneny-King A, et al. Among authors: edginton an. Pharmaceutics. 2017 Oct 17;9(4):47. doi: 10.3390/pharmaceutics9040047. Pharmaceutics. 2017. PMID: 29039750 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

132 results

Search Page

Filters